Kelonia Overview
- Year Founded
-
2021
- Status
-
Acquired/Merged
- Employees
-
62
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$7B
Kelonia General Information
Description
Developer of a genetic medicine platform designed to enable targeted delivery of therapeutic genetic material. The company's platform offers tissue-specific delivery technology, engineered viral systems, and in vivo cell therapy capabilities, enabling healthcare researchers and clinicians to develop and administer precise treatments for complex diseases.
Contact Information
Website
www.keloniatx.com(Operating Subsidiary)
Corporate Office
- 34 Farnsworth Street
- 3rd Floor
- Boston, MA 02210
- United States
Corporate Office
- 34 Farnsworth Street
- 3rd Floor
- Boston, MA 02210
- United States
Kelonia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 26-Jun-2026 | $7B | Completed | Clinical Trials - Phase 1 | ||
| 3. Early Stage VC (Series A) | 14-Apr-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | $7.5M | $7.5M | Completed | Clinical Trials - Phase 1 | ||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
Kelonia Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
Kelonia Comparisons
Industry
Financing
Details
Kelonia Competitors (1)
One of Kelonia’s competitors is Vir Biotechnology, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA |
Kelonia Patents
Kelonia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240150788-A1 | Lymphocyte targeted lentiviral vectors | Active | 26-Feb-2021 |
Kelonia Signals
Kelonia Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Crown Venture Fund | Venture Capital | Minority | ||
| Horizons Ventures | Venture Capital | Minority | ||
| LabCentral | Accelerator/Incubator | |||
| Venrock | Venture Capital | Minority |
Kelonia FAQs
-
When was Kelonia founded?
Kelonia was founded in 2021.
-
Where is Kelonia headquartered?
Kelonia is headquartered in Boston, MA.
-
What is the size of Kelonia?
Kelonia has 62 total employees.
-
What industry is Kelonia in?
Kelonia’s primary industry is Drug Discovery.
-
Is Kelonia a private or public company?
Kelonia is a Private company.
-
What is the current valuation of Kelonia?
The current valuation of Kelonia is .
-
What is Kelonia’s current revenue?
The current revenue for Kelonia is .
-
How much funding has Kelonia raised over time?
Kelonia has raised $57.5M.
-
Who are Kelonia’s investors?
Alta Partners, Crown Venture Fund, Horizons Ventures, LabCentral, and Venrock have invested in Kelonia.
-
Who are Kelonia’s competitors?
Vir Biotechnology is a competitor of Kelonia.
-
When was Kelonia acquired?
Kelonia was acquired on 26-Jun-2026.
-
Who acquired Kelonia?
Kelonia was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process